Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Clinilabs Drug Development Corporation | UNKNOWN |
| Drug Safety Navigator | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A: MDD Participants - CYB003 in 2 of 2 Medicine Sessions | Experimental | Arm A MDD participants will receive CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study. |
|
| B: MDD Participants - Placebo in Medicine Session 1, CYB003 in Medicine Session 2 | Placebo Comparator | Arm B MDD participants will receive placebo in Medicine Session 1, and approximately three weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study. |
|
| C: Healthy Volunteers - CYB003 in 2 of 2 Medicine Sessions | Experimental | Arm C healthy volunteers will receive CYB003 in 2 of 2 medicine sessions, approximately one to two weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study. |
|
| D: Healthy Volunteers - Placebo in Medicine Session 1, CYB003 in Medicine Session 2 | Placebo Comparator | Arm D healthy volunteers will receive placebo in Medicine Session 1, and approximately one to two weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CYB003 | Drug | CYB003 is a synthetic psilocybin analog. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events (All Arms) | Any untoward medical occurrence in a clinical investigation participant administered a drug and does not necessarily have a causal relationship with the treatment | Day 1 thru End of Study Visit (which is: Day 56 Arms A & B; Day 28 Arms C & D; Day 35 Arms E) |
| Resting 12 Lead ECG ventricular rate (Arms A & B) | ventricular rate (beats per minute) | Screening, Day -1, Day 1, Day 2, Day 21, Day 22, & Day 23 |
| Resting 12 Lead ECG ventricular rate (Arms C & D) | ventricular rate (beats per minute) | Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 |
| Resting 12 Lead ECG ventricular rate (Arms E) | ventricular rate (beats per minute) | Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 |
| Resting 12 Lead ECG PR interval (Arms A & B) | PR interval (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 |
| Resting 12 Lead ECG PR interval (Arms C & D) | PR interval (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 |
| Resting 12 Lead ECG PR interval (Arms E) | PR interval (milliseconds) | Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Mystical Experience Questionnaire (MEQ30) (Arms A & B) | The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. Each item is rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items. |
Not provided
Inclusion Criteria - MDD & Healthy Volunteer Participants:
Additional Inclusion Criteria - MDD Participants Only:
Exclusion Criteria - MDD & Healthy Volunteer Participants:
Additional Exclusion Criteria - Healthy Volunteers Only:
Additional Exclusion Criteria - MDD Participants Only:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Amir Inamdar, MBBS,DNB,MFPM | Cybin IRL Limited | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CenExel ACMR | Atlanta | Georgia | 30331 | United States | ||
| iResearch Atlanta |
Not provided
| Label | URL |
|---|---|
| New Jersey Site Recruitment Website. Please click on link to apply | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 3, 2025 | Jun 18, 2025 | 8 | ||
| Aug 18, 2025 |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D011613 | Psychotherapy |
| ID | Term |
|---|---|
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| E: Healthy Volunteers - CYB003 in 3 of 3 Medicine Sessions | Experimental | Arm E healthy volunteers will receive CYB003 in 3 of 3 medicine sessions, approximately one week apart from each other, to assess bioavailability and food effect. The CYB003 dose received will depend on the safety review committee selection/time of enrollment. All healthy volunteers will receive psychological support throughout the study. |
|
| Psychotherapy | Behavioral | Manualized psychotherapy (called EMBARK) performed by facilitators |
|
| Placebo | Drug | Placebo |
|
| Psychological Support | Behavioral | Manualized psychological support performed by facilitators |
|
| Resting 12 Lead ECG QRS duration (Arms A & B) | QRS duration (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 |
| Resting 12 Lead ECG QRS duration (Arms C & D) | QRS duration (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 |
| Resting 12 Lead ECG QRS duration (Arms E) | QRS duration (milliseconds) | Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 |
| Resting 12 Lead ECG QT interval (Arms A & B) | QT interval (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 |
| Resting 12 Lead ECG QT interval (Arms C & D) | QT interval (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 |
| Resting 12 Lead ECG QT interval (Arms E) | QT interval (milliseconds) | Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 |
| Resting 12 Lead ECG QTcF (Arms A & B) | Corrected QT interval by Fredericia (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 |
| Resting 12 Lead ECG QTcF (Arms C & D) | Corrected QT interval by Fredericia (milliseconds) | Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 |
| Resting 12 Lead ECG QTcF (Arms E) | Corrected QT interval by Fredericia (milliseconds) | Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 |
| Holter monitoring (Arms A & B) | Record of the electrical activity of the heart (Hz) | Day -1, Day 1, Day 22 |
| Holter monitoring (Arms C & D) | Record of the electrical activity of the heart (Hz) | Day -1, Day 1, Day 8 |
| Holter monitoring (Arm E) | Record of the electrical activity of the heart (Hz) | Day -1, Day 1, Day 8, Day 15 |
| Columbia Suicide Severity Rating Scale (CSSRS) Lifetime version (All Arms) | Evaluation tool that evaluates a lifetime history of suicidal ideation and/or behavior. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care). | Screening |
| Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms A & B) | Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care). | Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 38, Day 42, and Day 56 |
| Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms C & D) | Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care). | Day -1, Day 2, Day 7, Day 9, Day 15, Day 21, Day 28 |
| Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arm E) | Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care). | Day -1, Day 2, Day 7, Day 9, Day 14, Day 16, Day 21, Day 28, Day 35 |
| Day 1 & Day 22 |
| Mystical Experience Questionnaire (MEQ30) (Arms C & D) | The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. each item rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items. | Day 1 & Day 8 |
| Mystical Experience Questionnaire (MEQ30) (Arms C & D) | The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. each item rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items. | Day 1, Day 8, & Day 15 |
| 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arms A & B) | The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes. | Day 1 & Day 22 |
| 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arms C & D) | The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes. | Day 1 & Day 8 |
| 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arm E) | The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes. | Day 1, Day 8, & Day 15 |
| Hallucinogen Rating Scale (HRS) (Arms A & B) | The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect. | Day 1 & Day 22 |
| Hallucinogen Rating Scale (HRS) (Arms C & D) | The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect. | Day 1 & Day 8 |
| Hallucinogen Rating Scale (HRS) (Arm E) | The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect. | Day 1, Day 8, & Day 15 |
| Persisting Effects Questionnaire (PEQ) (Arms A & B) | The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects. | Day 1 & Day 22 |
| Persisting Effects Questionnaire (PEQ) (Arms C & D) | The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects. | Day 1 & Day 8 |
| Persisting Effects Questionnaire (PEQ) (Arm E) | The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects. | Day 1, Day 8, & Day 15 |
| VAS Ratings of "Any Drug Effect" (Arms A & B) | The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect. | Day 1 & Day 22 |
| VAS Ratings of "Any Drug Effect" (Arms C & D) | The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect. | Day 1 & Day 8 |
| VAS Ratings of "Any Drug Effect" (Arm E) | The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect. | Day 1, Day 8, & Day 15 |
| Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from screening (Arms A & B) | The minimum and maximum values are 0 and 60 with a higher score indicating a worse outcome. | Screening, Day -1, Day 1, Day 10, Day 17, Day 31, & Day 38 |
| Pharmacokinetic parameter of psilocin (Cmax) (Arms A & B) | Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data. | Day 1, Day 2, Day 22, & Day 23 |
| Pharmacokinetic parameter of psilocin (Cmax) (Arms C & D) | Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data. | Day 1, Day 2, Day 8, & Day 9 |
| Pharmacokinetic parameter of psilocin (Cmax) (Arm E) | Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data. | Day 1, Day 2, Day 8, Day 9, Day 15, & Day 16 |
| Pharmacokinetic parameter of psilocin (AUC) (Arms A & B) | AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule. | Day 1, Day 2, Day 22, & Day 23 |
| Pharmacokinetic parameter of psilocin (AUC) (Arms C & D) | AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule. | Day 1, Day 2, Day 8, & Day 9 |
| Pharmacokinetic parameter of psilocin (AUC) (Arm E) | AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule. | Day 1, Day 2, Day 8, Day 9, Day 15, & Day 16 |
| Decatur |
| Georgia |
| 30030 |
| United States |
| Clinilabs Drug Development Corporation | Eatontown | New Jersey | 07724 | United States |
| Sep 5, 2025 |
| 9 |
| Oct 30, 2025 | Nov 13, 2025 | 10 |
| Jan 2, 2026 | Jan 21, 2026 | 11 |
| Jun 18, 2026 |
| D001519 |
| Behavior |